Y-mAbs Therapeutics (YMAB) announced the presentation of preclinical and translational pharmacokinetics, PK, data of CD38-SADA in a poster at the 2025 American Association of Cancer Research, AACR, Annual Meeting being held on April 25-30, 2025 in Chicago, IL. The poster titled “Preclinical and translational pharmacokinetic modeling of the self-assembling and disassembling, SADA, bispecific fusion protein CD38-SADA for first-in-human pretargeted radioimmunotherapy” characterizes the plasma concentrations of CD38-SADA in animal models over time and a range of doses. Utilizing in vitro binding kinetic parameters and PK data generated from three studies in mice, the study characterized the concentration- and time-dependent equilibrium between CD38-SADA tetramers and monomers
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform
- Y-mAbs Therapeutics downgraded to Underperform from Neutral at BofA
- Y-mAbs downgraded to Underperform at BofA on tough near-term setup
- Y-Mabs Therapeutics: Promising Pipeline and Positive Financial Outlook Justify Buy Rating
- Y-mAbs Therapeutics price target lowered to $12 from $22 at H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue